<span id="b3inl"></span>
  • <i id="b3inl"><meter id="b3inl"></meter></i><rt id="b3inl"><optgroup id="b3inl"><strike id="b3inl"></strike></optgroup></rt>
    <span id="b3inl"><optgroup id="b3inl"></optgroup></span>
    <span id="b3inl"><optgroup id="b3inl"></optgroup></span>

    <span id="b3inl"><optgroup id="b3inl"></optgroup></span>
        您好!歡迎訪問貝達(dá)藥業(yè)官方網(wǎng)站。
        服務(wù)熱線:0571-86130357     加入收藏 | 在線反饋English
        新聞中心 / News Center
        《CHINA DAILY》:Betta applauds supportive moves in pharma sector
        日期: 2025-03-13

        Employees of Betta Pharmaceuticals work on a drug packaging line in Hangzhou, Zhejiang province. WANG GANG/CHINA NEWS SERVICE


        Chinese firms can accelerate clinical trials and bring their drugs to market faster with more supportive policies, challenging foreign monopolies and positioning themselves as leaders in global biopharma, said a national political adviser on the sidelines of the two sessions that ended on Tuesday.

        Ding Lieming, a member of the 14th National Committee of the Chinese People's Political Consultative Conference and chairman of Betta Pharmaceuticals Co Ltd, a leading innovative biopharma firm, recalled a pivotal moment in his company's rise in an interview with China Daily. In 2005, Betta faced a significant roadblock while submitting a clinical trial application for its oncology drug.

        The approval process at that time took up to two years, a timeline that hindered the company's R&D efforts. After turning to the Zhejiang provincial government for support, Betta's request was expedited, and approval was cut to just seven months.

        "As competition in the biopharma industry intensifies globally, China is leveraging its growing capabilities to take on established foreign players and reshape the global market," Ding said.

        Ding Lieming

        The company has set its sights on global markets, Ding added. In December, the United States approved Ensartinib, making it the first small-molecule targeted therapy for lung cancer independently developed and globally launched by a Chinese company.

        "We have also begun filing for approval of such drugs in Europe, marking a significant milestone in the company's international expansion," he disclosed.

        Founded in 2003, Betta has championed homegrown innovation, focusing on developing therapies that can compete internationally. Conmana, the company's flagship product and China's first small-molecule targeted cancer treatment, was approved in 2011 and has already improved the lives of over 700,000 lung cancer patients.

        While China's pharmaceutical industry is accelerating its global presence, Ding said that hurdles still remain, particularly in financing.

        He said: "Greater cooperation between government-led funds and industry investors is needed to bolster confidence in the pharmaceutical sector. It is also important to create flexible investment mechanisms and adopt long-term strategies to nurture patient capital that supports extended innovation cycles."

        Despite these challenges, Ding stressed the need to strengthen China's innovation ecosystem by fostering closer ties between academic research institutions and the pharmaceutical industry.

        To succeed on the global stage, Ding advocates a dual strategy: continuing to prioritize homegrown innovation, especially in cutting-edge fields like small-molecule targeted drugs, gene therapy and immunotherapy, while deepening international partnerships with global pharmaceutical companies, research institutions and regulatory agencies.

        Looking ahead, Ding said there were immense opportunities in leveraging China's advantages — its vast patient base, efficient supply chains and rapidly evolving approval processes.

        "Technological innovation is reshaping the global biopharma landscape," Ding said. "For Chinese companies to succeed, they must fully integrate into the international innovation ecosystem and challenge established global players head-on."


        上一條: 無
        下一條: 《中國日?qǐng)?bào)網(wǎng)》:從2年到7個(gè)月:中國創(chuàng)新藥如何闖關(guān)全球市場?
        熱門點(diǎn)擊
        主站蜘蛛池模板: 在线观看免费国产视频| 国产成人免费网站在线观看 | 亚洲爆乳无码专区www| 一本色道久久综合亚洲精品蜜桃冫 | 一级特黄色毛片免费看| 新最免费影视大全在线播放| 在线观看人成视频免费无遮挡 | 一级毛片免费全部播放| 狼友av永久网站免费观看 | 久久乐国产精品亚洲综合| 亚洲日韩小电影在线观看| 亚洲日本在线观看网址| 亚洲欧美日韩中文字幕在线一区| 国产成人亚洲精品蜜芽影院| 91成人免费福利网站在线| 亚洲成片观看四虎永久| 亚洲高清在线播放| 亚洲人成综合网站7777香蕉| 又硬又粗又长又爽免费看| 国产精品免费看久久久无码| 亚洲中文字幕无码av| 四虎成人免费大片在线| 久久国产精品亚洲综合| 国产午夜免费高清久久影院| 日本不卡高清中文字幕免费| 亚洲AV无码资源在线观看| 91在线手机精品免费观看| 国产又大又长又粗又硬的免费视频| 一区二区三区亚洲视频| 亚洲精品视频观看| 一级成人生活片免费看| 中文字幕日韩亚洲| 日本亚洲欧洲免费天堂午夜看片女人员 | 99国产精品视频免费观看| 国产人成免费视频| 噜噜噜亚洲色成人网站| 亚洲日产韩国一二三四区| **一级一级毛片免费观看| 国产亚洲精久久久久久无码AV| 成年免费a级毛片免费看无码| 国产精品免费小视频|